Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT07438626
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Phase II
  • SMARCB1-deficient Renal Medullary Carcinoma
  • Sacituzumab
  • Tirumotecan

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Sacituzumab tirumotecan — DRUG
    Given by IV

Study Details

To learn if sacituzumab tirumotecan can help to control advanced or metastatic SMARCB1-deficient RMC in patients whose disease has progressed after receiving at least 1 treatment.

Key Dates

First listed
Feb 27, 2026
Start date
Apr 27, 2026
Status verified
Feb 2026
Primary completion
Jun 1, 2028
Completion
Feb 1, 2030

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Single Arm
    Treatment with Sacituzumab Tirumotecan

Primary Outcome Measure

Safety and adverse events (AEs). [ Time Frame: Through study completion; an average of 1 year. ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
MD Anderson Cancer CenterHoustonTexas77030
Pavlos Msaouel, MD
[email protected]
713-563-4585
Pavlos Msaouel, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Houston, TX

By research site
MD Anderson Cancer Center· Houston, TX

Related Studies